Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 3/20 | 0.60 |
| ▸ | CCND3 | P30281 | 3/20 | 0.60 |
| ▸ | CDK9 | P50750 | 3/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CTSC | P53634 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26906721 | 0.80 | CDK9 (0.59) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL29904658 | 0.80 | CDK9 (0.59) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL19831454 | 0.78 | PTK2 (0.64) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL29904638 | 0.78 | CCNA2 (0.76) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL29904681 | 0.76 | PKMYT1 (0.55) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL26906640 | 0.76 | PKMYT1 (0.55) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL13300755 | 0.75 | CCNA2 (0.77) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL30394638 | 0.75 | CCNA2 (1.00) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL32690427 | 0.75 | CCNA2 (0.67) | CCNKCCND3CDK9CDK6CCNA2 | |
| SCHEMBL1682845 | 0.75 | PTK2 (0.49) | PTK2STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | claimed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | claimed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | claimed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | CCNK 193/4885CCND3 959/4885CDK9 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.